ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo. At the heart of its technology is its patented anti-aging glycopeptide AAGP. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.
Type | Public | |
Founded | 1999 | |
HQ | Marietta, OH, US | Map |
Website | protokinetix.com |
USD | |
---|---|
Net income (Q3, 2020) | (1.7m) |
Market capitalization (25-Jan-2021) | 36.7m |
Closing stock price (25-Jan-2021) | 0.1 |
Cash (30-Sept-2020) | 44.8k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
General and administrative expense | 201.0k | 119.4k | 95.8k | 141.5k | 126.8k | 99.6k | 105.3k | 78.1k | 280.4k |
R&D expense | 117.4k | 74.5k | 13.8k | 158.9k | 450.9k | 296.5k | 337.1k | 369.5k | |
Operating expense total | 318.4k | 119.4k | 170.3k | 155.3k | 285.7k | 550.5k | 401.8k | 415.1k | 650.0k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||||
General and administrative expense | 44.3k | 28.6k | 34.4k | 28.7k | 29.6k | 20.9k | 26.0k | 23.3k | 14.1k | 49.0k | 21.0k | 38.9k | 42.7k | 23.2k | 21.4k | 29.5k | 17.3k | 32.1k | 29.8k | 12.5k | 17.4k | 25.6k | 13.7k | 33.9k | 91.4k | 76.9k | 57.0k | 71.0k | 46.5k |
R&D expense | 13.4k | 18.3k | 18.3k | 18.3k | 12.9k | 2.1k | 53.0k | 19.1k | 29.9k | 71.7k | 108.5k | 175.0k | 69.0k | 86.2k | 72.9k | 84.6k | 70.5k | 92.8k | 63.5k | 74.7k | 140.9k | 219.5k | 76.8k | 142.2k | |||||
Operating expense total | 44.3k | 42.0k | 34.4k | 28.7k | 29.6k | 39.1k | 44.2k | 41.6k | 26.9k | 49.0k | 23.1k | 91.9k | 61.8k | 53.1k | 93.1k | 138.0k | 192.3k | 101.2k | 116.0k | 85.4k | 102.1k | 96.1k | 106.5k | 97.4k | 166.1k | 217.8k | 276.5k | 147.8k | 188.7k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.0k | 6.4k | 17.5k | 15.0k | 5.1k | 13.9k | 4.5k | 2.5k | 1.7k | 6.8k | 10.9k | 130.7k | 114.4k | 163.5k | 261.0k | 108.5k | 89.0k | 549.2k | 238.3k | 386.1k | 192.1k | 214.4k | 110.5k | 24.1k | 503.8k | 289.9k | 47.9k | 45.3k | 44.8k |
Accounts Receivable | 4.3k | 5.4k | 94.0 | 3.9k | 4.9k | 6.0k | 119.0 | 1.3k | 2.2k | 5.9k | 7.9k | 8.0k | 8.0k | 8.0k | |||||||||||||||
Prepaid Expenses | 9.0k | 39.8k | 2.2k | 731.0 | 1.9k | 18.6k | 13.6k | 3.6k | 1.9k | 1.9k | 1.5k | 880.0 | 637.0 | 167.0 | 154.6k | 91.4k | 25.9k | 142.5k | 97.7k | 58.7k | 62.5k | 11.1k | 21.7k | 45.6k | 10.6k | 1.1k | 1.1k | 1.1k | |
Current Assets | 138.0k | 123.2k | 172.1k | 269.2k | 271.1k | 180.4k | 575.1k | 380.8k | 483.9k | 250.8k | 276.9k | 121.6k | 45.9k | 549.4k | 300.4k | 48.9k | 46.4k | 45.8k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (1.2m) | (197.1k) | (448.6k) | (168.5k) | (1.3m) | (1.5m) | (1.5m) | (1.2m) | (4.2m) |
Depreciation and Amortization | 1.5k | 3.0k | 3.0k | 3.0k | 3.0k | ||||
Accounts Payable | (84.2k) | 28.0k | 82.6k | 128.3k | (18.2k) | (3.7k) | (14.8k) | 49.7k | (51.1k) |
Cash From Operating Activities | (396.6k) | (149.9k) | (105.3k) | (229.2k) | (574.2k) | (820.3k) | (605.1k) | (453.5k) | (850.7k) |
ProtoKinetix has 156 Twitter Followers. The number of followers has decreased 0.2% month over month and increased 1.3% quarter over quarter
242
Tweets
184
Following
156
Followers
4
Tweets last 30 days
1
Avg. likes per Tweet
100%
Tweets with engagement
When was ProtoKinetix founded?
ProtoKinetix was founded in 1999.
Who are ProtoKinetix key executives?
ProtoKinetix's key executives are Clarence E. Smith, Edward P. McDonough and Michael R. Guzzetta.
Who are ProtoKinetix competitors?
Competitors of ProtoKinetix include International Stem Cell Corporation, EpiVax and Transgene.
Where is ProtoKinetix headquarters?
ProtoKinetix headquarters is located at 412 Mulberry St, Marietta.
Where are ProtoKinetix offices?
ProtoKinetix has an office in Marietta.
How many offices does ProtoKinetix have?
ProtoKinetix has 1 office.
Receive alerts for 300+ data fields across thousands of companies